Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Clinical Hematology International|January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple MyelomaTorben Plesner, Simon J Harrison, Hang Quach, et al.
Annals of Hematology|July 3, 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Haematologica|September 4, 2025
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study GroupKari Lenita Falck Moore, Samundur Rognvaldsson, Agoston G Szabo, et al.
Blood Cancer Journal|January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
The Lancet. Oncology|February 5, 2021
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working GroupEvangelos Terpos, Elena Zamagni, Suzanne Lentzsch, et al.
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
European Journal of Haematology|September 18, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study GroupHenrik Gregersen, Valdas Peceliunas, Kari Remes, et al.
Experimental Hematology & Oncology|December 24, 2025
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53Klara Acs, Juho J Miettinen, Philipp Sergeev, et al.
Pageof 8